Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition capable of inhibiting TSLP secretion and alleviating allergic diseases

A technology for allergic diseases and compositions, applied in the field of compositions with TSLP secretion inhibitory properties and allergic disease improvement properties, can solve problems such as disappearance, and achieve the effect of excellent effect and excellent activity

Inactive Publication Date: 2016-03-02
LG HOUSEHOLD & HEALTH CARE LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] In view of the above situation, many researchers in Korea are currently researching and commercializing an improving agent for improving atopic dermatitis, but the phenomenon that most of the developed products disappear at the initial stage of entering the market is repeated.
The reason is that most of the products currently developed are not products developed corresponding to the pathological mechanism of inducing and exacerbating atopic dermatitis, but cosmetics that enhance skin moisturizing effect or have low skin irritation The reason for developing it as an improved product for atopy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition capable of inhibiting TSLP secretion and alleviating allergic diseases
  • Composition capable of inhibiting TSLP secretion and alleviating allergic diseases
  • Composition capable of inhibiting TSLP secretion and alleviating allergic diseases

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0079] In the preparation process of the health-care functional food composition, the amount of the compound represented by Chemical Formula 1 or its pharmaceutically acceptable salt added to the food can be adjusted as needed, but relative to 100% by weight For foods, the above-mentioned addition amount is preferably 1% by weight to 15% by weight, but is not limited thereto.

[0080] As another embodiment, the present invention provides a method for inhibiting TSLP secretion, which includes the step of administering the above-mentioned composition to an individual.

[0081] The term "administration" used in the present invention refers to providing the prescribed substance to the patient by any suitable method. For the administration route of the composition of the present invention, as long as it can reach the target tissue, any usual administration method can be adopted. way. Examples include skin application, intraperitoneal administration, intravenous administration, int...

Embodiment 1

[0087] Example 1: Evaluation of TSLP secretion inhibitory properties of human epidermal keratinocytes

[0088] Human epidermal keratinocytes were treated with rhein (Rhein), which is a compound represented by Chemical Formula 1 of the present invention, and cultured, and the TSLP secretion inhibitory effect was confirmed.

[0089] Each well of a 24-well plate was injected with 1×10 human epidermal keratinocytes. 4 After the individual cells were allowed to attach, they were cultured for 4 days, and when they reached more than 90%, they were replaced with a new culture solution added with calcium chloride at a concentration of 1.4 mM, and then cultured for another 2 days to induce cell differentiation. To induce TSLP secretion in differentiated cells, treatment with polyI:C 20 μg / mL was performed. Then, they were treated with rhein at 0.5 μg / mL, 1 μg / mL and 2 μg / mL respectively, and after 24 hours, the cell culture fluid was taken, and the concentration of TSLP was determined ...

Embodiment 2

[0091] Example 2: Evaluation of the cytotoxicity of the compound rhein represented by Chemical Formula 1

[0092] In order to analyze the cytotoxicity of rhein, after the treatment with each concentrated rhein, the viability of the cells was confirmed using a spectrophotometer.

[0093] Each well of a 24-well plate was injected with 1×10 human epidermal keratinocytes. 4 After the individual cells were allowed to attach, they were cultured for 4 days, and when they reached more than 90%, they were replaced with a new culture solution added with calcium chloride at a concentration of 1.4 mM, and then cultured for another 2 days to induce cell differentiation. Then, polyI:C was treated at 20 μg / mL, and rhein was treated with 0.5 μg / mL, 1 μg / mL, and 2 μg / mL, respectively, and cultured for 24 hours. After 24 hours, remove the medium, add 200 μl of medium and 20 μl of CCK8 solution to each well, and incubate at 37°C, CO 2 Incubate in ambient medium for 20 minutes, then measure abs...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition, a cosmetic composition, or a health functional food, which are capable of effectively alleviating allergic diseases by inhibiting the secretion of Thymic stromal lymphopoietin (TSLP) and inhibiting TSLP, and which include, as an active ingredient, a compound represented by chemical formula 1 of the present invention or a pharmaceutically acceptable salt. Accordingly, the composition has an excellent effect for inhibiting the secretion of TSLP, which is an immune reaction factor, and thus is superior for alleviating allergic diseases caused by an imbalance in the immune system.

Description

technical field [0001] The present invention relates to a compound that contains a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient, and has TSLP (Thymicstromallymphopoietin) secretion inhibitory properties, and through the above-mentioned TSLP secretion inhibitory properties, can treat diseases including atopic dermatitis, asthma, etc. , allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, urticaria and allergic diseases of food allergy have improved pharmaceutical composition, cosmetic material composition and health function food composition. Background technique [0002] In recent years, with the new environmental pollutants brought by industrial development, and the increase of indoor living chemical substances brought about by the popularization of man-made fibers, etc., skin diseases have also increased significantly. In particular, in recent years, with changes in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/122A61P17/00A61P11/06A61P11/00
CPCA61K8/368A61K31/192A61K2800/74A61Q19/00A23L33/10A61P11/00A61P11/06A61P17/00A61K31/122
Inventor 金允善李相和
Owner LG HOUSEHOLD & HEALTH CARE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com